Abstract
This review summarizes target populations of neonates for which erythropoietin (Epo) neuroprotective therapy might be of benefit, and the mechanisms by which Epo functions as a neuroprotective agent. Potential risks of Epo are reviewed. Finally, the progression of Epo neuroprotection from preclinical studies to translational studies is discussed.
MeSH terms
-
Brain / drug effects
-
Brain / metabolism
-
Erythropoietin / administration & dosage
-
Erythropoietin / metabolism
-
Erythropoietin / physiology*
-
Erythropoietin / therapeutic use
-
Humans
-
Hypoxia-Ischemia, Brain / etiology
-
Hypoxia-Ischemia, Brain / prevention & control
-
Infant, Newborn / metabolism*
-
Infant, Newborn, Diseases / etiology
-
Infant, Newborn, Diseases / prevention & control
-
Infant, Premature, Diseases / etiology
-
Infant, Premature, Diseases / prevention & control
-
Nervous System Diseases / etiology
-
Nervous System Diseases / prevention & control
-
Neuroprotective Agents* / administration & dosage
-
Neuroprotective Agents* / adverse effects
-
Neuroprotective Agents* / metabolism
-
Neuroprotective Agents* / therapeutic use
-
Risk Factors
Substances
-
Neuroprotective Agents
-
Erythropoietin